Antidiabetic and Antidyslipidemic Activities of Dryopteris Filix-Mas Methanol Leaf Extract in Alloxan-Induced Diabetic Rats doi.org/10.26538/tjnpr/v5i12.22

Main Article Content

Ejiro P. Awhin
Alfred I. Ajoh
Blessing Erutere

Abstract

Diabetes mellitus, a chronic metabolic disease with significant morbidity and mortality, has been associated with changes in lipid profile. Dryopteris filix-mas has been widely explored in treatment and management of various disorders. The antidiabetic and antidyslipidemic effects of Dryopteris filix-mas in alloxan-induced diabetic rats were investigated in Wistar rats. Thirty (30)adults male Wistar rats used were grouped into: 1 (Normal control); 2 (Untreated alloxan induced-diabetic rats); 3 (Diabetic rats administered 500mg/kg metformin); 4 (Diabetic rats administered 100mg/kg Dryopteris filix methanol leaf extract). 5 (Diabetic rats administered 250mg/kg Dryopteris filix methanol leaf extract); 6 (Diabetic rats administered 500 mg/kgDryopteris filix methanol leaf extract). The rats were sacrificed after 21 days. The serum was used for biochemical assay of glucose, cholesterol, triglyceride, high density lipoprotein (HDL)and low-density lipoprotein (LDL), using standard procedures. Dryopteris filix leaf extract significantly (p<0.05) reduced blood glucose levels in rats after initial increase in glucose following diabetes induction. Induction of diabetes in rats significantly (p<0.05) increased serum cholesterol, triglyceride and LDL levels, while significantly reducing HDL levels in diabetic rats. However, administration of varying doses of Dryopteris filix-mas extract significantly (p<0.05) decreased levels of cholesterol, triglyceride and LDL with corresponding increase in level of HDL. The observed changes compared well with the group administered metformin.mThe methanol leaf extract of Dryopteris filix-mas, thus, improved serum lipid profile, in diabetic rats, along with having antihyperglycemic activity. 

Downloads

Download data is not yet available.

Article Details

Section

Articles

How to Cite

P. Awhin, E., I. Ajoh, A., & Erutere, B. (2021). Antidiabetic and Antidyslipidemic Activities of Dryopteris Filix-Mas Methanol Leaf Extract in Alloxan-Induced Diabetic Rats: doi.org/10.26538/tjnpr/v5i12.22. Tropical Journal of Natural Product Research (TJNPR), 5(12), 2170-2173. http://mail.tjnpr.org/index.php/home/article/view/282

References

Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, populationbased study. Br Med J. 2001; 332(7299):1389-1393.

NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: A pooled analysis of 751 populationbased studies with 4.4 million participants. Lancet. 2016; 387(10027):1513-1530.

Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes Dyslipidemia. Diabetes Ther. 2016; 7(2):203-219.

Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and treatment of dyslipidemia in diabetes. Curr Cardiol Rep. 2021; 23(4):26.

Sofowora A. Medicinal plants and traditional medicine in Africa. John Wiley & Sons ltd. New York. 1982.

Tagarelli G, Tagarelli A, Piro A. Folk medicine used to heal malaria in Calabria (southern Italy). J Ethnobiol Ethnomed.2010; 6(27):1-16.

Uwumarongie HO, Enike MA, Bafor EE. Pharmacognostic evaluation and gastrointestinal activity of D. filix-mas. Ewemen J Herb Chem Pharmacol Res. 2016; 2(1):19-25.

Erhirhie EO, Ilodigwe EE, Ajaghaku DL, Umeokoli BO, Eze PM. Antioxidant Activities of the Leaf Extract and Fractions of Dryopteris filix-mas (L.) Schott could be Attributed to The Abundance of Polyphenol Compounds. Biol Med Nat Prod Chem. 2020; 9(1):1-6.

Erhirhie EO, Emeghebo CN, Ilodigwe EE, Ajaghaku DL, Umeokoli BO, Eze PM, Ngwoke KG, Okoye FBC. Dryopteris filix-mas (L.) Schott ethanolic leaf extract and fractions exhibited profound anti-inflammatory activity. Avicenna J Phytomed. 2019; 9(4):396-409.

Erhirhie E, Anyim C, Okezie M, Igboeme S, Ilodigwe E. Evaluation of Wound Healing Properties of Dryopteris filix-mas Leaf and Root Extracts on Albino Rats. Iran J Pharm Sci. 2021; 17(1):79-90.

Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4):470-475.

Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. HDL Cholesterol and Other Lipids in Coronary Heart Disease: Cooperative Lipoprotein Phenotyping Study. Circul. 1977; 55(5):767-772.

Fossati P and Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982; 28(1):2077-2080.

Friendewald WT, Levy RT, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502.

Lenzen S. The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia. 2008; 51(2):216-226.

Macdonald IO, Mohammed AA, Adeboye AO. Alloxaninduced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Med. 2017; 53(6):365-374.

Musi N, Hirshman MF, Nygren J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51(7):2074-2081.

Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000; 59(7):887-890.

Song, R. Mechanism of Metformin: A tale of two sites. Diabetes Care. 2016; 39(2):187-189.

Buse JB, DeFronzo RA, Rosenstock J. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016; 39(2):198–205.

Saudek CD and Young NL. Cholesterol metabolism in diabetes mellitus. Diabetes. 1981; 30(2):76-81.

Nikkila EA and Hormila P. Serum lipids and lipoproteins in insulin treated diabetes. Diabetes. 1978; 27(11):1078-1086.